Disclosures for "Progressive Multifocal Leukoencephalopathy (PML) in an Immunocompetent Host with Excellent Clinical Response to Pembrolizumab Therapy: A Case Report"
-
Dr. Rothenberg has nothing to disclose.
-
Dr. Robers has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Robers has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. Robers has received research support from National Multiple Sclerosis Society. The institution of Dr. Robers has received research support from Bristol Myers Squibb Foundation. The institution of Dr. Robers has received research support from Barrow Neurological Foundation.
-
Dr. Hoskin has nothing to disclose.